Comparison of the Pretreatment Effects of Mixed Vasodilators (3-D Solution) on Radial and Internal Thoracic Arteries by Using a 3-Dimensional Anaglyph Electron Microscope Technique
DOI:
https://doi.org/10.1532/HSF98.2006-1006Abstract
Objective. Currently, internal thoracic arteries (ITA) and radial arteries (RA) are the first choice of conduits for coronary artery bypass grafts (CABG). Because the perioperative vasospasm continues to be a major problem, a number of pharmacologic agents such as papaverine, calcium receptor blockers, nitroglycerine, and phenoxybenzamine have been suggested as topical antispasmodics that may be used in the pre- and postoperative periods. In the present study, we investigated the quantitative efficacies of the mixed solution, which included verapamil, nitroglycerin, and papaverine, on RA and ITA using a scanning electron microscope with a 3-dimensional anaglyph technique.
Methods. Diameter changes of RA and ITA in response to clinically important vasodilators were measured on 40 RA and 40 ITA rings from patients who had been subjected to coronary artery bypass procedure after 20 minutes of ex vivo incubation with verapamil (45 ?g/L), nitroglycerin (45 ?g/L), papaverine solution (266 ?mol/L or 0.1 ?/mL), and 30 mL autologous heparinized whole blood (individual patient's blood obtained before cardiopulmonary bypass contained 100 IU of heparin per kg of patient weight). The pretreatment action was assessed by measuring the response to vasodilators.
Results. In all cases, we did not observe graft vasospasm in any of the conduits during the intraoperative period between postanastomosis and sternal closure. In the postoperative period, we did not record any evidence of ischemic change in patients' electrocardiographic and myocardial enzyme analyses. None of the cases required inotropic support after the operation. The diameters of the pretreated RA and ITA were: minimum, 2.1 mm; maximum, 4.0 mm; and mean value, 2.80 ± 0.46 mm. The diameters of the pretreated ITA were: minimum, 1.2 mm; maximum, 2.5 mm; and mean value, 1.76 ± 0.35 mm. Incubated arterial segment diameters for the RA were: minimum, 2.8 mm; maximum, 5.2 mm; and mean value, 3.95 ± 0.65 mm. These values for the ITA were: minimum, 1.5 mm; maximum, 3.9 mm; and mean value, 2.37 ± 0.50 mm. These findings were statistically significant for both arterial grafts (P <.05).
Conclusions. According to our study findings, the mixed solution demonstrates a broad range of efficacy. We conclude that the described vasodilator solution with heparinized autologous blood seems to be very effective and may be used as a pretreatment agent in CABG conduits. Although papaverine has the shortest duration of action, its efficiency is increased by verapamil and nitroglycerin, in our opinion. To the best of our knowledge, high-quality imaging of CABG conduits with the 3-D anaglyph technique using a scanning electron microscope was a first in the literature. This technical approach may be used for confirming the ultrastructural anatomy and the quantitative vasodilator effects of arterial conduits. We believe that valuable anatomo-pathologic details of the CABG conduit can be obtained by this technique.
References
Chardigny C, Jebara VA, Acar C, et al. 1993. Vasoreactivity of the radial artery. Comparison with the internal mammary and gastroepiploic arteries with implications for coronary artery surgery. Circulation88:115-27nChester AH, Marchbank AJ, Borland JA, Yacoub MH, Taggart DP. 1998. Comparison of the morphologic and vascular reactivity of the proximal and distal radial artery. Ann Thorac Surg66:1972-7nDipp MA, Nye PC, Taggart DP. 2001. Phenoxybenzamine is more effective and less harmful than papaverine in the prevention of radial artery vasospasm. Eur J Cardiothorac Surg19:482-6nHarrison WE, Mellor AJ, Clark J, Singer DR. 2001. Vasodilator pre-treatment of human radial arteries: comparison of effects of phenoxybenzamine vs papaverine on norepinephrine-induced contraction in vitro. Eur Heart J22:2209-16nHe GW, Buxton BF, Rosenfeldt FL, Angus JA, Tatoulis J. 1994. Pharmacologic dilatation of the internal mammary artery during coronary bypass grafting. J Thorac Cardiovasc Surg107:1440-4nHe GW, Rosenfeldt FL, Angus JA. 1993. Pharmacological relaxation of the saphenous vein during harvesting for coronary artery bypass grafting. Ann Thorac Surg55:1210-7nHe GW, Yang CQ. 1997. Radial artery has higher receptor-mediated contractility but similar endothelial function compared with mammary artery. Ann Thorac Surg63:1346-52nHe GW, Yang CQ. 1996. Use of verapamil and nitroglycerin solution in preparation of radial artery for coronary grafting. Ann Thorac Surg61: 610-4nMinami K, Korner MM, Vyska K, Kleesiek K, Knobl H, Korfer R. 1990. Effects of pulsatile perfusion on plasma catecholamine levels and hemo-dynamics during and after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg99:82-91nReyes AT, Frame R, Brodman RF. 1995. Technique for harvesting the radial artery as a coronary artery bypass graft. Ann Thorac Surg59: 118-26nTaggart DP, Dipp M, Mussa S, Nye PC. 2000. Phenoxybenzamine prevents spasm in radial artery conduits for coronary artery bypass grafting. J Thorac Cardiovasc Surg120:815-7nTaylor KM, Brannan JJ, Bain WH, Caves PK, Morton IJ. 1979. Role of angiotensin II in the development of peripheral vasoconstriction during cardiopulmonary bypass. Cardiovasc Res13:269-73nvan Son JA, Smedts F, Vincent JG, van Lier HJ, Kubat K. 1990. Comparative anatomic studies of various arterial conduits for myocardial revascularization. J Thorac Cardiovasc Surg99:703-7nVelez DA, Morris CD, Muraki S, et al. 2001. Brief pretreatment of radial artery conduits with phenoxybenzamine prevents vasoconstriction long term. Ann Thorac Surg72:1977-84nAcar C, Jebara VA, Portoghese M, et al. 1992. Revival of the radial artery for coronary artery bypass grafting. Ann Thorac Surg54:652-60n
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
